Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 1 of 3 (33%) have an AI response strategy ready • 2 patents granted in the last 365 days
Maxcyte Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units. Suraj Sapkota is the busiest examiner for the company, handling 1 of the pending office actions. The prosecution for Maxcyte Inc. is currently spread across several different examiners.
The 3 pending office actions for Maxcyte Inc. are each assigned to a different examiner, resulting in several distinct examiners for the portfolio. These actions are also located in 3 distinct art units, indicating a diverse range of technical review within the Biotechnology & Pharmaceuticals sector. Suraj Sapkota is one of the examiners, managing a single pending office action. This arrangement prevents any single examiner from having a disproportionate impact on the company's overall prosecution success, as the workload is split among multiple individuals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAPKOTA, SURAJ | 1 | 0.0% | +0.0% |
| FERNANDEZ, SUSAN EMILY | 1 | 52.3% | +60.9% |
| WHITEMAN, BRIAN A | 1 | 68.4% | +16.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694640 | A METHOD OF ENHANCED VIRAL TRANSDUCTION USING ELECTROPORATION | SAPKOTA, SURAJ | — |
| 17288719 | METHODS TO IMPROVE POTENCY OF ELECTROPORATION | WHITEMAN, BRIAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17661480 | SEQUENTIAL ELECTROPORATION METHODS | FERNANDEZ, SUSAN EMILY | — |
| 17288719 | METHODS TO IMPROVE POTENCY OF ELECTROPORATION | WHITEMAN, BRIAN A | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1651 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18694640 | A METHOD OF ENHANCED VIRAL TRANSDUCTION USING ELECTROPORATION | SAPKOTA, SURAJ | 1635 | §103 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 17661480 | SEQUENTIAL ELECTROPORATION METHODS | FERNANDEZ, SUSAN EMILY | 1651 | §103 | Final Rejection | — | AI Ready | Apr 29, 2022 |
| 17288719 | METHODS TO IMPROVE POTENCY OF ELECTROPORATION | WHITEMAN, BRIAN A | 1600 | §102§103§112 | Non-Final OA | — | Pending | Apr 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMaxcyte Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Suraj Sapkota has the most, with 1 of Maxcyte Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
